Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The clinical utility of inhibiting CD28‐mediated costimulation

Linsley, Peter S., Nadler, Steven G.·2009·Immunological Reviews

Abstract

Summary: This volume covers many topics in the field of T‐cell costimulation. The need for such a volume is testament to the growth of the field. From its beginning as a concept in the 1980s, we have now progressed to the point where many molecules now have functionally defined roles in T‐cell costimulation. In addition, the field has progressed ‘from bench to bedside’. Abatacept [cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)‐immunoglobulin (Ig) (CTLA‐4‐Ig)], an inhibitor of CD28‐mediated T‐cell costimulation, was approved for the treatment of moderate‐to‐severe rheumatoid arthritis in 2006 by the Food and Drug Administration and in 2007 by the European Medicines Agency. This chapter first presents a personal historical perspective on the early basic studies on the elucidation of the CD28/B7 T‐cell costimulatory pathway and the discovery of CTLA‐4‐Ig. We next present an overview of studies of CTLA‐4‐Ig in preclinical animal studies. The material discussed in these first two sections is selective rather than exhaustive; their purpose is to provide context for the final section, a summary of human clinical studies performed with abatacept.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-065x.2009.00780.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 162

Metadata

Authors
Linsley, P. S., & Nadler, S. G.
Venue
Immunological Reviews
Publisher
Wiley
Published
2009-04-21
Volume
229
Issue
1
Pages
307-321
ISSN
  • 0105-2896 (ISSN-L)
  • 1600-065X
OpenAlex
W2108758471
Cited by
162
References
2
FWCI
0.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The clinical utility of inhibiting CD28‐mediated costimulation. https://app.cochat.ai/papers/10.1111/j.1600-065x.2009.00780.x
The paper
Linsley, P. S., & Nadler, S. G. (2009). The clinical utility of inhibiting CD28‐mediated costimulation. Immunological Reviews. https://doi.org/10.1111/j.1600-065x.2009.00780.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.